Abcam gains after securing all approvals for Danaher sale, set to close Dec. 6
5.12BUSD
Type
Common Stock
Exchange
PINK
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
-
CUSIP
-
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
June
IPO date
-
Updated At
-
PE Ratio
2,225.00
PEG Ratio
-
Book Value
3.14
Dividend Share
-
Dividend Yield
-
Earnings Share
0.01
Wall Street Target Price
-
EPS Estimate Current Year
0
EPS Estimate Next Year
0
EPS Estimate Current Quarter
0
EPS Estimate Next Quarter
0
Most Recent Quarter
-
Revenue TTM
379,700,000
Gross Profit TTM
270,500,000
EBITDA
106,000,000
Profit Margin
0.66%
Return On Assets TTM
4.36%
Return On Equity TTM
0.35%
Revenue Per Share TTM
1.658
Qtly Revenue Growth YOY
9.70%
Diluted Eps TTM
0.01
Qtly Earnings Growth YOY
188.00%
Trailing PE
2225.00
Forward PE
32
Price Sales TTM
13.4866
Price Book MRQ
5.6658
Enterprise Value Revenue
11
Enterprise Value EBITDA
67
169.54
3.19%82.72
1.87%414.00
0.56%694.59
0.56%86.83
0.51%240.51
0.02%655.00
0.00%194.85
0.00%34.16
-0.86%97.63
-0.27%Abcam gains after securing all approvals for Danaher sale, set to close Dec. 6
Abcam ticks higher amid report of China approval for sale to Danaher
Shareholders of Abcam approve proposed acquisition by Danaher
Abcam holder Starboard Value said to sell stake - report
Abcam holders should vote for sale to Danaher, proxy adviser ISS says
Abcam received multiple bids in sales process, contacted over 30 parties